NRX Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $242 | $0 | $4 | $4 |
Gross Profit | 145 | 2 | -1 | |
EBITDA | -5,864 | -17,581 | -5,512 | -9,077 |
EBIT | -5,890 | -3,730 | -9,078 | -9,078 |
Net Income | -5,890 | -17,581 | -5,512 | -9,078 |
Net Change In Cash | 242 | 0 | 4 | 4 |
Free Cash Flow | -2,891 | -4,028 | -3,480 | -2,098 |
Cash | 7,184 | 2,910 | 5,548 | 1,443 |
Basic Shares | 22,231 | 17,934 | 16,410 | 10,517 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -5 | -5 | -4 | -2 |
EBITDA | -24,042 | -30,025 | -39,750 | -93,043 |
EBIT | -24,047 | -30,030 | -39,754 | -93,045 |
Net Income | -25,126 | -30,150 | -39,754 | -93,063 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -10,637 | -21,660 | -39,765 | -37,710 |
Cash | 1,443 | 4,595 | 20,054 | 27,605 |
Basic Shares | 10,517 | 7,576 | 65,767 | 46,918 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.50 |
2025-06-30 | -$0.98 |
2025-03-31 | -$0.34 |
2024-12-31 | -$0.77 |
